Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
San Diego Pacific Oncology & Hematology Associates
OBJECTIVES: * Compare relapse-free and overall survival of patients with high-risk stage III melanoma receiving adjuvant sorafenib tosylate, tamoxifen citrate, and cisplatin vs historical data from patients treated with tamoxifen citrate and cisplatin. * Compare the toxicity of these regimens in these patients. OUTLINE: This is a pilot study. Patients are stratified according to number of positive lymph nodes identified during surgery. Patients receive oral sorafenib tosylate twice daily on days 1-28, oral tamoxifen citrate twice daily on days 1-7, and cisplatin IV over 1 hour on days 2 and 3. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed periodically for at least 5 years.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
